Can reduced thyroid hormone signaling lower energy expenditure and contribute to fatigue, weight gain, reduced activity, and muscle dysfunction?

Reduced thyroid-hormone signaling is clinically relevant chiefly in overt hypothyroidism, where it can contribute to a lower metabolic rate, fatigue, modest weight change, and muscle symptoms. The claim is plausible overall, with the strongest support for overt—not subclinical—disease.

Clinical evidence

• Overt hypothyroidism is associated with reduced resting energy expenditure, which generally increases as thyroid status is normalized. Observational data in euthyroid volunteers also associate higher free T3 with higher resting energy expenditure, though this does not establish clinically important effects from small variations within the reference range.
• Fatigue, muscle weakness, cramps, and impaired muscle function are recognized manifestations of overt hypothyroidism. These symptoms can reasonably reduce voluntary activity, although direct activity-measurement evidence is limited.
• Weight gain in untreated overt hypothyroidism is usually modest. Retained salt and water can account for a substantial portion of the change; weight loss after replacement should not be interpreted as evidence that thyroid hormone is a general weight-loss treatment.

Limits across thyroid states

• Findings should not be generalized to subclinical hypothyroidism or to people whose thyroid tests are within reference ranges.
• In a randomized trial of 737 older adults with subclinical hypothyroidism, levothyroxine did not improve tiredness, weight, BMI, handgrip strength, or daily functioning at 1 year.
• A meta-analysis of 21 randomized trials similarly found no meaningful benefit for fatigue, muscle strength, or BMI in subclinical hypothyroidism.

Bottom line

• Material thyroid-hormone deficiency can contribute to lower energy expenditure, fatigue, modest weight gain, reduced activity, and impaired muscle function. However, these nonspecific symptoms alone do not demonstrate reduced thyroid signaling, and treatment benefits for these outcomes have not been shown in subclinical hypothyroidism.